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ABSTRACT
McCune-Albright syndrome (MAS) is a rare disease characterized by a triad of fibrous 
dysplasia, cafe-au-lait spots and peripheral precocious puberty. We reported a 5-year-
8-month old girl with MAS who has been followed-up for 2 years and 8 months. She 
was referred to pediatric endocrinology clinic in our hospital for vaginal bleeding at age 
of 2 years 11 months. She had peripheral precocious puberty, i.e. increased estrogen 
level associated with very low gonadotropins, and cafe-au-lait spots on her face and was 
diagnosed as MAS. The patient was treated with estrogen receptor blocker (tamoxifen). 
She had no menses during the 2 years and 8 months of tamoxifen treatment. Her growth 
rate and bone maturation were also in normal ranges. However, at the end of tamoxifen 
treatment she had an episode of vaginal bleeding so that we had to change to other 
treatment modalities.
ABSTRAK
Sindrom McCune-Albright merupakan penyakit langka yang ditandai dengan trias 
displasia fibrosa, makula cafe-au-lait dan pubertas prekok perifer. Kami melaporkan 
anak perempuan usia 5 tahun 8 bulan yang telah kami amati selama 2 tahun 8 bulan. 
Pasien datang ke poliklinik endokrinologi di rumah sakit kami dengan keluhan perdarahan 
pervaginam pada usia 2 tahun 11 bulan. Ia mengalami pubertas prekok perifer yang 
ditandai dengan peningkatan kadar estrogen dan rendahnya kadar gonadotropin,, makula 
cafe-au-lait, dan didiagnosis dengan sindrom McCune-Albright. Pasien diterapi dengan 
penghambat reseptor estrogen (tamoxifen). Selama terapi, siklus menstruasi terhenti, 
kecepatan pertumbuhan dan maturasi tulang dalam batas normal. Namun pada akhir 
terapi dengan tamoxifen, pasien kembali mengalami perdarahan pervaginam sehingga 
kami harus mengganti dengan modalitas terapi yang lain.
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INTRODUCTION
McCune-Albright syndrome (MAS) 
is a genetic disorder characterized by 
abnormalities in skin pigmentation, endocrine 
system, and bone growth due to the GNAS 
(guanine nucleotide binding protein, alpha 
stimulating) gene mutations.1,2 Prevalence 
of the disease ranged from 1:100.000 to 
1:1.000.000 worldwide.3 Classically, this 
syndrome presents with triad of fibrous 
dysplasia, typical skin pigmentation (cafe-
au-lait), and endocrinopathies, including 
precocious puberty, hyperthyroidism, 
Cushing’s syndrome, growth hormone excess, 
hyperprolactinemia, hyperparathyroidism, 
and/or rickets or osteomalacia. 
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Precocious puberty was the most com-
mon endocrinopathy found in MAS. It oc-
curs in 64-79% of girls and 15% of boys.4 
Aromatase inhibitors, e.g. testolactone, 
fadrazole, anastrozole, and letrozole, se-
lective estrogen receptor modulators, e.g. 
tamoxifen, analogue of gonadotropin-re-
leasing hormone (GnRH), and surgery were, 
so far, the suggested modalities to manage 
precocious puberty associated with MAS.5 
However, due to the rareness of the disease, 
the experience of using any of the above mo-
dalities are very limited. In this case report, 
we present a 2-years-8-month follow-up of 
tamoxifen use in a patient with peripheral 
precocious puberty of MAS.
CASE
A 2-years-11-month-girl, presented to 
pediatric endocrinology clinic at Sardjito 
General Hospital due to vaginal bleeding. 
The bleeding last for 2-3 days. On physical 
examination, we found breast enlargement 
(Tanner stage 2) and cafe-au-lait spots on 
her face. The child’s height was 87,0 cm 
(plotted at -1.8 SD on the WHO child growth 
standard 2006). We observed low levels 
of gonadotropins, i.e. luteinizing hormone 
(LH) <0.1 mIU/mL (normal values: 2.4-
12.6 mIU/mL, follicle-stimulating hormone 
(FSH) of 0.109 mIU/mL (normal values: 
3.5-12.5 mIU/mL) and increased level of 
estradiol (635 pg/mL, normal values: 6-20 
pg/mL). Bone age, assessed by Greulich-
Pyle method, was equivalent to 2 years old. 
Pelvic ultrasound examination revealed post 
pubertal uterine size (2.57 x 2.67 x 1.73 cm), 
however, the ovaries were unvisualized. 
There was no history of pathological 
fracture. Based on the presence of peripheral 
precocious puberty and cafe-au-lait spots on 
the face, patient was diagnosed as MAS.
FIGURE 1. Cafe-au-lait skin pigmentation on the face
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Treatment with tamoxifen (20 mg/
day) was started immediately following 
the diagnosis. The menstrual bleeding was 
ceased shortly after the initiation of therapy. 
The serum estradiol level measured one year 
after the treatment declined to less than 5 pg/
mL. Pelvic ultrasound examination carried 
out one year after the treatment showed 
smaller uterine size (2.71 x 2.21 x 1.20 cm). 
The ovaries were also unvisualized.
After 2 years and 8 months of regular 
treatment with single dose of tamoxifen 
20 mg/day, the child had an episode of 
vaginal bleeding and breast enlargement, 
accompanied by pubic hair growth (Tanner 
stage 2). Evaluation of endocrine function 
observed low levels of gonadotropins (LH 
0.1 mIU/mL, FSH 0.8 mIU/mL) and normal 
level of estradiol (5 pg/mL). Bone age was 
equivalent to 5 years old, which was still in-
line for chronological age of 5 years and 8 
months. On pelvic ultrasound examination, 
the uterine size increased compared to the 
last evaluation (3.79 x 2.17 x 1.96 cm), and 
the ovaries were still unvisualized.
The child has been growing well. 
Currently, at the age of 5 years and 8 
months, she was 112.0 cm in height 
and 19.0 kg in weight (equal to -0.8 SD 
and -0.5 SD, respectively, on the WHO 
growth standard 2006), and has achieved 
Tanner stage of B2 and P2. The growth 
velocity was 7.5 cm/year during the last 2 
years (95% confidence interval of growth 
velocity in pre-pubertal girls is 5.1-9.3 cm/
year). During the observation, no other 
endocrinopathies that often accompany MAS 
(Cushing’s syndrome, hyperprolactinoma, 
hyperthyroidism, and growth hormone 
excess) were observed. Thyroid ultrasound, 
and TSH and FT4 levels were normal. There 
were no bone abnormalities suggesting 
fibrous dysplasia. No pathological fracture 
was observed, but at the age of 4 years there 
was an open second metatarsal fracture on 
the left foot, coincidently due to motorcycle 
accident. The fracture completely healed 
without deformity or gait impairment after 
surgical treatment of open reduction and 
internal fixation.
DISCUSSION
MAS is characterized by a triad of fibrous 
dysplasia, cafe-au-lait spots, and precocious 
puberty. Other endocrinopathies such as 
hyperthyroidism, growth hormone excess, 
Cushing’s syndrome, hyperprolactinemia, 
and rickets or osteomalacia may also occur, 
as well as other involvement of the liver, 
parathyroid, pancreas, and heart.6 MAS is 
associated with mutation in the GNAS1 gene, 
which is mapped to chromosome 20q13.3. 
The protein product is involved in G-protein 
signaling.2 The mutation in the GNAS gene 
occurs randomly during pregnancy and will 
result in mosaic of normal and mutated 
cells.1,7 The manifestation and the severity of 
this disease depends on the number and the 
location of the cells expressing the mutated 
gene. The mutation influences activity 
of the related organ system at the level of 
interaction between hormones and receptor.2
Precocious puberty is the most 
common endocrinopathy found in MAS. 
Precocious puberty affects more girls than 
boys, characterized by premature vaginal 
bleeding. The precocious puberty was 
peripheral in origin, that is the hypothalamic-
pituitary-gonadal axis was not active. 
The pathogenesis involves autonomous 
activation of ovarian tissue lead to estrogen 
hypersecretion. However, progression into 
central precocious puberty may also occur.5,8
Therapeutic options include the use 
of anti-estrogen (aromatase inhibitor, 
e.g. testolactone, fadrozole, anastrozole, 
andletrozole), estrogen receptor inhibitor 
(e.g. tamoxifen), analogue of GnRH (if there is 
a progression to central precocious puberty), 
and surgery (unilateral oophorectomy, 
cystectomy).5 A multicenter study on the use 
of tamoxifen for precocious puberty in girls 
with MAS for one year has shown a decrease 
in vaginal bleeding episodes and significant 
improvements of growth velocity and bone 
maturation.9
We treated our patient with tamoxifen 
and observed good response during the 
first and second year of treatment. She 
had no menses, and her growth rate and 
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bone maturation were in normal ranges. 
However, on third year (after 2-years-and-
8-month treatment) she suddenly had new 
episode of vaginal bleeding and breast 
enlargement, accompanied by pubic hair 
growth, despite regular treatment with 
tamoxifen. In fact, the patient had good 
adherence to the treatment, as we evaluated 
using the Medication Morisky Adherence 
scale (MMAS-8).10 We decided to change 
to other treatment modalities since, to the 
best of our knowledge, there is no study 
so far on the safety of using higher dose of 
tamoxifen. Hormonal evaluation after the 
vaginal bleeding revealed no increase in 
gonadotropin level, therefore, progression to 
central precocious puberty can be ruled out.
Nunez et al.11 reported that fadrazole 
was not effective for the treatment of 
precocious puberty and causing adrenal 
insufficiency. Meanwhile, Feuillan et al.12 
reported that testolactone may be used as 
a therapy for precocious puberty since it 
leads to a decrease in ovarian volume and 
estrogen concentration. However, one 
study13, which evaluates the long-term 
therapy of testolactone, shows some patients 
have persistent symptoms of puberty, 
suggesting incomplete inhibitory effects of 
estrogen production. Other study14 indicates 
that letrozole is an effective medication 
for precocious puberty in MAS. Recently, 
Estrada et al.15 shows that letrozole has good 
long-term effect for precocious puberty in 
MAS in reducing episodes of menstruation 
and keeping the skeletal maturation and 
growth velocity so that predicted adult 
height can be achieved.
Based on those recent studies on the 
long-term effects letrozole in girls with 
precocious puberty in MAS, we changed 
the medication for our patient to letrozole 
following the failure of two-year-treatment 
with tamoxifen. We started the treatment 
with letrozole at dose of 1.25 mg/day since 
March 2017, and continuing to observe the 
result. 
CONCLUSION
The diagnosis of MAS must be kept 
in mind in cases with gonadotropin-
independent precocious puberty. Radiologic 
and laboratory assessments should be 
performed in order to investigate the 
presence of accompanying endocrinological 
and non-endocrinological disorders. A 
careful clinical observation and follow 
up of patients with mentioned clinical 
presentations is necessary.
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